<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00195793</url>
  </required_header>
  <id_info>
    <org_study_id>M03-661</org_study_id>
    <nct_id>NCT00195793</nct_id>
  </id_info>
  <brief_title>A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Prospective, Parallel Study to Compare the Safety and Efficacy of Fenofibrate or Ezetimibe as Add-On Therapy to Atorvastatin in Subjects With Combined Hyperlipidemia, Typical of the Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effects of adding Tricor 145 mg to once daily&#xD;
      atorvastatin 20 mg on CHD lipid laboratory parameters.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2004</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from Combination Baseline to 12 weeks post-Combination Baseline in direct measured HDL-C and TG.</measure>
    <time_frame>Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Advanced lipid and inflammatory parameters</measure>
    <time_frame>Week 12</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">174</enrollment>
  <condition>Hyperlipidemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fenofibrate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is &gt;= 18 years of age, any race, and any gender.&#xD;
&#xD;
          -  Subjects must have the following fasting parameters:&#xD;
&#xD;
               -  LDL-C &gt; 100 mg/dL and &lt; 190 mg/dL.&#xD;
&#xD;
               -  TG level &gt;= 175 mg/dL and &lt; 1000 mg/dL.&#xD;
&#xD;
               -  HDL-C &lt; 40 mg/dL (men) and &lt; 50 mg/dL (women).&#xD;
&#xD;
          -  Subjects must have one or more of the following:&#xD;
&#xD;
               -  Treated or untreated hypertension defined as blood pressure (BP)&#xD;
&#xD;
               -  130 mmHg &gt;= 85 mmHg (systolic / diastolic).&#xD;
&#xD;
               -  Waist circumference &gt; 88 cm (35 inches) for women or &gt; 102 cm (40 inches) for&#xD;
                  men.&#xD;
&#xD;
               -  Fasting glucose defined as &gt;= 100 mg/dL but &lt;= 125 mg/dL.&#xD;
&#xD;
          -  Subject has, in the opinion of the investigator, a life expectancy greater than 6&#xD;
             months.&#xD;
&#xD;
          -  Female subjects must have a negative pregnancy test prior to study enrollment.&#xD;
&#xD;
          -  Female subjects of child bearing potential must agree to practice an effective barrier&#xD;
             method of birth control for the duration of the study.&#xD;
&#xD;
          -  Subject must be willing to observe the Step I Diet recommended by the NCEP throughout&#xD;
             the study.&#xD;
&#xD;
          -  Subject must be willing to participate in the study and to complete all follow-up&#xD;
             assessments.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a known hypersensitivity to fenofibrate, ezetimibe, or atorvastatin&#xD;
&#xD;
          -  Subject has been previously enrolled in this study.&#xD;
&#xD;
          -  Subject has used an investigational drug within 30 days of study entry.&#xD;
&#xD;
          -  Subject has been diagnosed with Type I or Type II Diabetes Mellitus or is currently&#xD;
             being treated with anti-diabetic medication, or has a fasting glucose &gt;= 126 mg/dL.&#xD;
&#xD;
          -  Subject has a history of pancreatitis or cholelithiasis or a history of gastric or&#xD;
             duodenal ulcer within 3 months of study entry.&#xD;
&#xD;
          -  Subject has hematologic, digestive, or central nervous system disorder including&#xD;
             cerebrovascular disease or degenerative disease that would limit study evaluation or&#xD;
             participation.&#xD;
&#xD;
          -  Subject has had a myocardial infarction, coronary bypass surgery, or angioplasty&#xD;
             within 6 months of study entry.&#xD;
&#xD;
          -  Subject has unstable or severe peripheral artery disease within 3 months of study&#xD;
             entry.&#xD;
&#xD;
          -  Subject has unstable angina pectoris or uncontrolled cardiac arrhythmias.&#xD;
&#xD;
          -  Subject has congestive heart failure (CHF) as defined by NYHA Class III or IV&#xD;
&#xD;
          -  Subject has coagulopathy (PT or PTT &gt; 1.25 times control).&#xD;
&#xD;
          -  Subject has known impairment of renal function (serum creatinine &gt; 1.5 mg/dL),&#xD;
             dysproteinemia, nephrotic-range proteinuria, or other renal disease.&#xD;
&#xD;
          -  Subject has active or chronic hepatobiliary or hepatic disease (subjects with AST or&#xD;
             ALT &gt; 2 times the upper limit of the central laboratory reference range).&#xD;
&#xD;
          -  Subject is pregnant or lactating.&#xD;
&#xD;
          -  Subject is receiving hormonal therapy.&#xD;
&#xD;
          -  Subject has a known history of thyroid disease or other endocrine abnormality.&#xD;
&#xD;
          -  Subject has a history of diagnosed hereditary or acquired myopathy.&#xD;
&#xD;
          -  Subject is known to be HIV positive.&#xD;
&#xD;
          -  Subject has a history of mental instability, drug or alcohol (as defined by greater&#xD;
             than 14 drinks per week) abuse, or subject has been treated for severe psychiatric&#xD;
             illness, which, in the opinion of the investigator, may interfere with optimal&#xD;
             participation in the study.&#xD;
&#xD;
          -  Subject has received a solid organ transplant.&#xD;
&#xD;
          -  Subject has a clinically significant, unstable, uncontrolled disease that could be&#xD;
             adversely affected by study participation.&#xD;
&#xD;
          -  Subject is unwilling or unable to consent to enter the study.&#xD;
&#xD;
          -  Subject is, in the opinion of the investigator, unable to comply with the requirements&#xD;
             of the study protocol or is unsuitable for the study for any reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Medical Information</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <verification_date>October 2007</verification_date>
  <study_first_submitted>September 14, 2005</study_first_submitted>
  <study_first_submitted_qc>September 14, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>October 2, 2007</last_update_submitted>
  <last_update_submitted_qc>October 2, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2007</last_update_posted>
  <keyword>Hyperlipidemia</keyword>
  <keyword>fenofibrate</keyword>
  <keyword>ezetimibe</keyword>
  <keyword>atorvastatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

